Clinical Trial Update: A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial update evaluating a new posaconazole dosing regimen for paediatric patients with Cystic Fibrosis and Aspergillosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aspergillosis
• Cystic Fibrosis

Drugs mentioned

• POSACONAZOLE (POSACONAZOLE)

Snippet

Sponsor: Bambino Gesù Hospital and Research Institute | Conditions: Cystic Fibrosis, Aspergillosis | Phase 2, Phase 3 | Status: UNKNOWN